HK1224311A1 - 受體抗原結合蛋白質及其應用 - Google Patents
受體抗原結合蛋白質及其應用Info
- Publication number
- HK1224311A1 HK1224311A1 HK16112546.6A HK16112546A HK1224311A1 HK 1224311 A1 HK1224311 A1 HK 1224311A1 HK 16112546 A HK16112546 A HK 16112546A HK 1224311 A1 HK1224311 A1 HK 1224311A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- binding proteins
- receptor antigen
- antigen
- receptor
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361839458P | 2013-06-26 | 2013-06-26 | |
PCT/US2014/044164 WO2014210205A1 (en) | 2013-06-26 | 2014-06-25 | Cb1 receptor antigen-binding proteins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1224311A1 true HK1224311A1 (zh) | 2017-08-18 |
Family
ID=51177217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16112546.6A HK1224311A1 (zh) | 2013-06-26 | 2016-11-01 | 受體抗原結合蛋白質及其應用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10227406B2 (zh) |
EP (1) | EP3013860B1 (zh) |
JP (5) | JP6562912B2 (zh) |
AU (1) | AU2014302410B2 (zh) |
CA (1) | CA2915386A1 (zh) |
HK (1) | HK1224311A1 (zh) |
WO (1) | WO2014210205A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3122780B1 (en) | 2014-03-27 | 2022-03-09 | Bird Rock Bio, Inc. | Antibodies that bind human cannabinoid 1 (cb1) receptor |
CN108513615B (zh) * | 2015-09-30 | 2022-03-08 | 鸟石生物公司 | 结合人大麻素1(cb1)受体的抗体 |
AU2018279950A1 (en) * | 2017-06-09 | 2020-01-30 | President And Fellows Of Harvard College | Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders |
WO2019070901A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | IMMUNOGLOBULIN FUSIONS OF TRANSTHYRETIN |
PE20210419A1 (es) | 2018-04-30 | 2021-03-08 | Takeda Pharmaceuticals Co | Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas |
JP7430624B2 (ja) | 2020-11-27 | 2024-02-13 | 株式会社ブリヂストン | タイヤ組立体 |
WO2023234406A1 (ja) * | 2022-06-03 | 2023-12-07 | 塩野義製薬株式会社 | カンナビノイド1型受容体に結合する抗体 |
WO2024022478A1 (zh) * | 2022-07-28 | 2024-02-01 | 长春金赛药业有限责任公司 | 结合大麻素受体cb1的抗体及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023232A2 (en) * | 2003-09-04 | 2005-03-17 | Affibody Ab | Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders. |
US7655685B2 (en) * | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
AU2009330206A1 (en) * | 2008-12-23 | 2011-07-07 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives as GPCR modttlators for use in the treatment of obesity and diabetes |
US20130059890A1 (en) * | 2009-12-18 | 2013-03-07 | Sydney West Area Health Service | Antiviral agents |
-
2014
- 2014-06-25 JP JP2016524170A patent/JP6562912B2/ja active Active
- 2014-06-25 WO PCT/US2014/044164 patent/WO2014210205A1/en active Application Filing
- 2014-06-25 CA CA2915386A patent/CA2915386A1/en active Pending
- 2014-06-25 EP EP14739018.1A patent/EP3013860B1/en active Active
- 2014-06-25 US US14/899,551 patent/US10227406B2/en active Active
- 2014-06-25 AU AU2014302410A patent/AU2014302410B2/en active Active
-
2016
- 2016-11-01 HK HK16112546.6A patent/HK1224311A1/zh unknown
-
2018
- 2018-08-28 JP JP2018159121A patent/JP2018201516A/ja not_active Withdrawn
-
2020
- 2020-09-11 JP JP2020152622A patent/JP7018104B2/ja active Active
-
2021
- 2021-12-13 JP JP2021201683A patent/JP2022037087A/ja not_active Withdrawn
-
2023
- 2023-09-07 JP JP2023145208A patent/JP2023171760A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3013860B1 (en) | 2018-12-12 |
JP6562912B2 (ja) | 2019-08-21 |
CA2915386A1 (en) | 2014-12-31 |
JP7018104B2 (ja) | 2022-02-09 |
JP2018201516A (ja) | 2018-12-27 |
AU2014302410B2 (en) | 2019-06-13 |
WO2014210205A1 (en) | 2014-12-31 |
JP2020196763A (ja) | 2020-12-10 |
JP2023171760A (ja) | 2023-12-05 |
US10227406B2 (en) | 2019-03-12 |
JP2016523910A (ja) | 2016-08-12 |
US20160145333A1 (en) | 2016-05-26 |
EP3013860A1 (en) | 2016-05-04 |
JP2022037087A (ja) | 2022-03-08 |
AU2014302410A1 (en) | 2015-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261743B (en) | and their uses 33–il antibodies against | |
HK1232243A1 (zh) | 抗- 抗體及其用途 | |
IL261547B (en) | Antibodies against pesidine and their uses | |
IL245040B (en) | Antibodies against pdgfr-beta and their uses | |
IL243974A0 (en) | Antibodies against -prlr and uses | |
ZA201508896B (en) | Anti-c10orf54 antibodies and uses thereof | |
IL246287A0 (en) | Fabs antibodies one by one and their uses | |
EP2970505A4 (en) | SPECIFIC ANTIBODIES AND USES THEREOF | |
SG11201509116VA (en) | Anti-tweakr antibodies and uses thereof | |
HK1224311A1 (zh) | 受體抗原結合蛋白質及其應用 | |
HRP20180664T1 (hr) | Nova protutijela protiv receptora fc-gama iib i njihova upotreba | |
HK1223950A1 (zh) | 單克隆 抗體及其用途 | |
ZA201603596B (en) | Fabs-in-tandem immunoglobulin and uses thereof |